The 7 most recent market catalysts affecting $AKTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 13, 2026
Corporate Catalyst
Neutral
Impact 75
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Progress
Akari Therapeutics announced its Q3 2026 financial results, reporting a net loss and a critically low cash balance of $5.7 million. Despite positive preclinical data for its TROP2-…
Nov 11, 2026
Corporate Catalyst
Neutral
Impact 55
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
Akari Therapeutics announced the appointment of Vatnak Vat-Ho as Chief Business Officer, a move that signals a potential strategic shift or renewed focus on business development, p…
Oct 31, 2026
Corporate Catalyst
Neutral
Impact 60
Akari Therapeutics to Present RNA-Splicing ADC Payload Strategy at 3rd Annual ADC Payload Summit
Akari Therapeutics announced that it will present its novel RNA-splicing disrupting payload strategy at an industry summit in November 2026. This is significant because it highligh…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
Akari Therapeutics shares are trading higher after the company highlighted progress toward AKTX-101 Phase 1 development and growing demand for its PH1 ADC payload platform.
This headline indicates a strong positive corporate catalyst for Akari Therapeutics. Progress in Phase 1 development for AKTX-101 suggests the drug is moving closer to market, whil…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
Akari Therapeutics has released encouraging preclinical data for AKTX-101, its novel TROP2-directed ADC, showing significant tumor inhibition in urothelial cancer models, including…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
Akari Therapeutics has entered a research collaboration with Whitehawk Therapeutics to investigate combining Akari's PH1 spliceosome modulating payload platform with Whitehawk's to…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC Platform
Akari Therapeutics has entered into a strategic research collaboration with Whitehawk Therapeutics. This collaboration focuses on preclinical studies to combine Akari's novel PH1 s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.